What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @AurelieRheumo: We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >

      Aurelie Najm AurelieRheumo

      4 years ago
      We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >12 months of TNFi treatment in the previous 2 years associated w/ ⬇️ radiographic progression of SIJ in r- and nr-axSpA in GESPIC, #Abst0174 @RheumNow #ACR21 https://t.co/2V1q4dUwFO https://t.co/lxQU4zAP1I
      RT @uptoTate: Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted

      Dr. Rachel Tate uptoTate

      4 years ago

      Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV

      RT @RichardPAConway: Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLa

      Richard Conway RichardPAConway

      4 years ago
      Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA
      RT @DrMiniDey: #Fatigue is common in pts w/ #PsA- what is the impact on short-term disability?

      Study of ~1200 pts finds

      Mrinalini Dey DrMiniDey

      4 years ago
      #Fatigue is common in pts w/ #PsA- what is the impact on short-term disability? Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs. @RheumNow #ACR21 Abs#0239 https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1
      RT @RheumDr_Nina: 📌Pre-Test Probability in GCA

      ESR/CRP can be normal:
      ~10% of pts at diagnosis
      -20-40% at time or

      Nina Couette RheumDr_Nina

      4 years ago
      📌Pre-Test Probability in GCA ESR/CRP can be normal: ~10% of pts at diagnosis -20-40% at time or relapse #ACR21 #ACRAmbassador #RheumTwitter https://t.co/kenaD31pYa
      RT @bella_mehta: Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst03

      Bella Mehta bella_mehta

      4 years ago
      Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst0324 https://t.co/67HBT7F2GO
      RT @RichardPAConway: Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Mos

      Richard Conway RichardPAConway

      4 years ago
      Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
      RT @RichardPAConway: Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare mo

      Richard Conway RichardPAConway

      4 years ago
      Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
      RT @KDAO2011: Don't wait!
      DR. Petri wants us to change paradigm of how we treat aggressive lupus nephritis: early, agg

      TheDaoIndex KDAO2011

      4 years ago
      Don't wait! DR. Petri wants us to change paradigm of how we treat aggressive lupus nephritis: early, aggressive, and multimodal. Does not matter if you add on VCS or BLMB, just don't treat LN with MMF monotherapy. #ACR21 #GreatDebate @rheumnow https://t.co/ebSiic095h
      RT @DrMiniDey: #Flu vaccine coverage remains low in patients with #rheumatoidarthritis.

      Results from @earlyarthritis Ab

      Mrinalini Dey DrMiniDey

      4 years ago
      #Flu vaccine coverage remains low in patients with #rheumatoidarthritis. Results from @earlyarthritis Abs#0141 https://t.co/DoZl5xyq2Q How can we increase vaccine uptake in our patients? @RheumNow https://t.co/nldA63EcVW
      RT @_Castillo_Pedro: #ACR2021
      Remember, one reason belimumab is so safe is that it does not completely deplete B cells.

      Pedro Castillo _Castillo_Pedro

      4 years ago
      #ACR2021 Remember, one reason belimumab is so safe is that it does not completely deplete B cells. Particularly important in times of COVID19. Dr. Petri #GreatDebate @RheumNow
      RT @RichardPAConway: Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think

      Richard Conway RichardPAConway

      4 years ago
      Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
      RT @uptoTate: Cluster analysis in axSpA pts classified 2 groups (predominantly axial vs peripheral dz) and showed lower

      Dr. Rachel Tate uptoTate

      4 years ago
      Cluster analysis in axSpA pts classified 2 groups (predominantly axial vs peripheral dz) and showed lower TNFi drug survival rates in those with prominent extra-axial manifestations. Abs 0365 #ACR21 #RheumNow @RheumNow https://t.co/ArgQ7mNqeD https://t.co/XqF7rPneMV
      RT @AurelieRheumo: 🔥 Ready for the next level of imaging? The radio-labelled tracer binding to integrin αvβ3 99mTc-

      Aurelie Najm AurelieRheumo

      4 years ago
      🔥 Ready for the next level of imaging? The radio-labelled tracer binding to integrin αvβ3 99mTc-maraciclatide is able to detect hypervascularization in RA joints and correlates w/ PDUS findings ⭐️ Sens 78% ⭐️ See 91% Fancy, yet more invasive than US! #Abst0174 @RheumNow #ACR21 https://t.co/eCOxjJsERh
      RT @uptoTate: 3/4 axSpA EMAS pts had/perceived to have employment challenge. Poor physical/mental health, lower educatio

      Dr. Rachel Tate uptoTate

      4 years ago
      3/4 axSpA EMAS pts had/perceived to have employment challenge. Poor physical/mental health, lower education, hx job change due to axSpA associated w/difficulties/perceived difficulties. Earlier dx/rx AND advocacy needed. Abs 0366 #ACR21 #RheumNow @RheumNow https://t.co/dlGhOymxVQ https://t.co/CWD6U1vRE0

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×